The use of Idarucizumab for dabigatran reversal in clinical practice: A case series

Pavel Goriacko, Vicken Yaghdjian, Issam Koleilat, Mark Sinnett, Harshal Shukla

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To describe the use of idarucizumab (Praxbind, Boehringer Ingelheim) in routine clinical practice at a large urban academic medical center. Summary: Seven total doses of idarucizumab were administered to six unique patients from October 31, 2015, to October 31, 2016. The reversal agent was used in conjunction with local bleeding control measures, blood product transfusions, and acid-suppressive therapy. In 86% of cases, idarucizumab administration resulted in a successful cessation of bleeding by clinical assessment. Two patients expired due to coexisting conditions. Idarucizumab was administered to patients with normal baseline coagulation tests in 43% of cases. No adverse reactions related to idarucizumab were reported. Conclusions: Idarucizumab administration resulted in successful resolution of bleeding by clinical assessment. The therapy for acute bleeding with use of dabigatran (Pradaxa, Boehringer Ingelheim) remains supportive care, in addition to idarucizumab in cases of severe or uncontrolled bleeding. Development of institution-specific protocols and better guidance for using baseline coagulation tests are needed.

Original languageEnglish (US)
Pages (from-to)699-704
Number of pages6
JournalP and T
Volume42
Issue number11
StatePublished - Nov 1 2017

Fingerprint

Hemorrhage
idarucizumab
Dabigatran
Blood Transfusion
Acids
Therapeutics

Keywords

  • Anticoagulants
  • Dabigatran
  • Hemorrhage
  • Idarucizumab
  • Reversal

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Goriacko, P., Yaghdjian, V., Koleilat, I., Sinnett, M., & Shukla, H. (2017). The use of Idarucizumab for dabigatran reversal in clinical practice: A case series. P and T, 42(11), 699-704.

The use of Idarucizumab for dabigatran reversal in clinical practice : A case series. / Goriacko, Pavel; Yaghdjian, Vicken; Koleilat, Issam; Sinnett, Mark; Shukla, Harshal.

In: P and T, Vol. 42, No. 11, 01.11.2017, p. 699-704.

Research output: Contribution to journalArticle

Goriacko, P, Yaghdjian, V, Koleilat, I, Sinnett, M & Shukla, H 2017, 'The use of Idarucizumab for dabigatran reversal in clinical practice: A case series', P and T, vol. 42, no. 11, pp. 699-704.
Goriacko P, Yaghdjian V, Koleilat I, Sinnett M, Shukla H. The use of Idarucizumab for dabigatran reversal in clinical practice: A case series. P and T. 2017 Nov 1;42(11):699-704.
Goriacko, Pavel ; Yaghdjian, Vicken ; Koleilat, Issam ; Sinnett, Mark ; Shukla, Harshal. / The use of Idarucizumab for dabigatran reversal in clinical practice : A case series. In: P and T. 2017 ; Vol. 42, No. 11. pp. 699-704.
@article{986ea00df922431e99bef0d5a51a759a,
title = "The use of Idarucizumab for dabigatran reversal in clinical practice: A case series",
abstract = "Purpose: To describe the use of idarucizumab (Praxbind, Boehringer Ingelheim) in routine clinical practice at a large urban academic medical center. Summary: Seven total doses of idarucizumab were administered to six unique patients from October 31, 2015, to October 31, 2016. The reversal agent was used in conjunction with local bleeding control measures, blood product transfusions, and acid-suppressive therapy. In 86{\%} of cases, idarucizumab administration resulted in a successful cessation of bleeding by clinical assessment. Two patients expired due to coexisting conditions. Idarucizumab was administered to patients with normal baseline coagulation tests in 43{\%} of cases. No adverse reactions related to idarucizumab were reported. Conclusions: Idarucizumab administration resulted in successful resolution of bleeding by clinical assessment. The therapy for acute bleeding with use of dabigatran (Pradaxa, Boehringer Ingelheim) remains supportive care, in addition to idarucizumab in cases of severe or uncontrolled bleeding. Development of institution-specific protocols and better guidance for using baseline coagulation tests are needed.",
keywords = "Anticoagulants, Dabigatran, Hemorrhage, Idarucizumab, Reversal",
author = "Pavel Goriacko and Vicken Yaghdjian and Issam Koleilat and Mark Sinnett and Harshal Shukla",
year = "2017",
month = "11",
day = "1",
language = "English (US)",
volume = "42",
pages = "699--704",
journal = "Hospital Therapy",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "11",

}

TY - JOUR

T1 - The use of Idarucizumab for dabigatran reversal in clinical practice

T2 - A case series

AU - Goriacko, Pavel

AU - Yaghdjian, Vicken

AU - Koleilat, Issam

AU - Sinnett, Mark

AU - Shukla, Harshal

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose: To describe the use of idarucizumab (Praxbind, Boehringer Ingelheim) in routine clinical practice at a large urban academic medical center. Summary: Seven total doses of idarucizumab were administered to six unique patients from October 31, 2015, to October 31, 2016. The reversal agent was used in conjunction with local bleeding control measures, blood product transfusions, and acid-suppressive therapy. In 86% of cases, idarucizumab administration resulted in a successful cessation of bleeding by clinical assessment. Two patients expired due to coexisting conditions. Idarucizumab was administered to patients with normal baseline coagulation tests in 43% of cases. No adverse reactions related to idarucizumab were reported. Conclusions: Idarucizumab administration resulted in successful resolution of bleeding by clinical assessment. The therapy for acute bleeding with use of dabigatran (Pradaxa, Boehringer Ingelheim) remains supportive care, in addition to idarucizumab in cases of severe or uncontrolled bleeding. Development of institution-specific protocols and better guidance for using baseline coagulation tests are needed.

AB - Purpose: To describe the use of idarucizumab (Praxbind, Boehringer Ingelheim) in routine clinical practice at a large urban academic medical center. Summary: Seven total doses of idarucizumab were administered to six unique patients from October 31, 2015, to October 31, 2016. The reversal agent was used in conjunction with local bleeding control measures, blood product transfusions, and acid-suppressive therapy. In 86% of cases, idarucizumab administration resulted in a successful cessation of bleeding by clinical assessment. Two patients expired due to coexisting conditions. Idarucizumab was administered to patients with normal baseline coagulation tests in 43% of cases. No adverse reactions related to idarucizumab were reported. Conclusions: Idarucizumab administration resulted in successful resolution of bleeding by clinical assessment. The therapy for acute bleeding with use of dabigatran (Pradaxa, Boehringer Ingelheim) remains supportive care, in addition to idarucizumab in cases of severe or uncontrolled bleeding. Development of institution-specific protocols and better guidance for using baseline coagulation tests are needed.

KW - Anticoagulants

KW - Dabigatran

KW - Hemorrhage

KW - Idarucizumab

KW - Reversal

UR - http://www.scopus.com/inward/record.url?scp=85032930773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032930773&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85032930773

VL - 42

SP - 699

EP - 704

JO - Hospital Therapy

JF - Hospital Therapy

SN - 1052-1372

IS - 11

ER -